Endocrinology Search
Endocrinology Endocrinology
adrenal%20insufficiency
ADRENAL INSUFFICIENCY
Adrenal insufficiency (AI) is the insufficient secretions of corticosteroids that may cause partial or complete destruction of the adrenal glands.
Primary AI or Addison’s disease is due to the inability of the adrenal gland to produce steroid hormones even when the stimulus by the pituitary gland via corticotrophin is adequate or increased.
Secondary AI is due to disorders of the pituitary gland that causes production of low levels of adrenocorticotropic hormone that will result to reduced cortisol levels.
Tertiary AI is the inability of the hypothalamus to produce sufficient amount of corticotropin releasing hormone.
Signs and symptoms are usually nonspecific with insidious onset.
Common signs and symptoms are fatigue, weakness, salt craving, orthostatic hypotension, nausea, vomiting, abdominal pain, diarrhea, anorexia and weight loss.

Adrenal Insufficiency Drug Information

Drug Information

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Adjuvant of maintenance therapy & short-term administration in psoriatic arthritis, ankylosing spondylitis...

Indication: Severe hypersensitivity & dermatological reaction; severe acute & chronic inflammatory & allergic ...

Indication: In situations requiring rapid & intense hormonal effect eg, acute adrenocortical insufficiency, bilateral ...

Indication: Adjunctive therapy for short-term management of acute episode or exacerbation post-traumatic OA, synovitis or ...

Indication: Primary or secondary adrenocortical insufficiency; endocrine, rheumatic, collagen, dermatologic, ophth, resp, ...

Indication: Replacement therapy for adrenocortical failure or hypopituitarism. Prior to dental surgery, or if shock, sever...

1  /  2
1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm
11 May 2020
This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.
Zinc supplementation improves glycaemic control in persons with, at risk of diabetes
Stephen Padilla, 22 Jul 2019
Zinc supplementation significantly lowers key glycaemic indicators, particularly fasting glucose (FG) in individuals with diabetes and in those who received an inorganic supplement, results of a systematic review and meta-analysis have shown.
Increased exercise tied to lower mortality risk in adults with T2D
Elaine Soliven, 15 Oct 2020

Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.
Detection of dysfunctional pancreatic beta cells in T1D feasible with GLP-1R imaging
Elvira Manzano, 07 Oct 2020
Exendin-4 imaging targeting GLP-1* receptor (GLP-1R) ably detects residual, dysfunctional pancreatic beta cells in individuals with long-standing type 1 diabetes (T1D), according to a study presented at EASD 2020. This breakthrough brings research closer to the possibility of restoring insulin-producing cells depleted in T1D.